ADRB2, adrenoceptor beta 2, 154

N. diseases: 387; N. variants: 17
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0004096
Disease: Asthma
Asthma
0.500 Biomarker disease BEFREE β2-Adrenergic receptor (β2AR) agonists are clinically used to elicit rapid bronchodilation for the treatment of bronchospasms in pulmonary diseases such as asthma and COPD, both of which exhibit characteristically high levels of reactive oxygen species (ROS); likely secondary to over-expression of ROS generating enzymes and chronically heightened inflammation. 31697929 2020
CUI: C0004096
Disease: Asthma
Asthma
0.500 GeneticVariation disease BEFREE Chronic stress has also been shown to result in biological changes such as expression of immunologic genes, changes in expression of the beta-adrenergic (B2AR) and the glucocorticoid receptor (GR-α) genes, cytokine regulation, and alterations in the hypothalamic pituitary axis and cortisol levels which all may affect asthma pathophysiology and therapeutic response among patients exposed to chronic stress. 31079340 2019
CUI: C0004096
Disease: Asthma
Asthma
0.500 GeneticVariation disease BEFREE The related papers on ADRB2 polymorphisms and asthma were systematically reviewed in databases of PubMed, EMBASE, Cochrane Library, and WanFang, Odds ratios (ORs) and corresponding 95% confidence intervals (95% CIs) were measured. 31115019 2019
CUI: C0004096
Disease: Asthma
Asthma
0.500 GeneticVariation disease BEFREE The meta-analysis suggests that the ADRB2 rs1042714 polymorphism has a protective association with asthma in the overall population and the pediatric subgroup. 31699066 2019
CUI: C0004096
Disease: Asthma
Asthma
0.500 Biomarker disease BEFREE Clinical management of asthma and chronic obstructive pulmonary disease (COPD) has primarily relied on the use of beta 2 adrenergic receptor agonists (bronchodilators) and corticosteroids, and more recently, monoclonal antibody therapies (biologics) targeting specific cytokines and their functions. 31379597 2019
CUI: C0004096
Disease: Asthma
Asthma
0.500 AlteredExpression disease BEFREE Upregulation of microRNA‑16 alters the response to inhaled β‑agonists in patients with asthma though modulating expression of ADRB2. 30942450 2019
CUI: C0004096
Disease: Asthma
Asthma
0.500 GeneticVariation disease BEFREE CONCLUSIONS The C79G polymorphism of the ADRB2 gene encoding ß2-AR was associated with a reduced risk for the development of pediatric asthma, particularly in the Asian population. 31142730 2019
CUI: C0004096
Disease: Asthma
Asthma
0.500 PosttranslationalModification disease BEFREE Increased β2-adrenoceptor phosphorylation in airway smooth muscle in severe asthma: possible role of mast cell-derived growth factors. 30069878 2018
CUI: C0004096
Disease: Asthma
Asthma
0.500 Biomarker disease BEFREE β2-adrenoreceptor agonist (β2AA) are widely used for the treatment of asthma. 30114199 2018
CUI: C0004096
Disease: Asthma
Asthma
0.500 Biomarker disease BEFREE Genetic variation in the β<sub>2</sub>-adrenergic receptor (ADRB2) gene has been thought to have an important role in the differential response to β<sub>2</sub>-agonist therapy for asthma. 28964817 2018
CUI: C0004096
Disease: Asthma
Asthma
0.500 Biomarker disease BEFREE We examined associations between the 4-gene model (IL13, IL4, FCER1B, and ADRB2) and the Asthma Predictive Index (API) and atopy in Chinese Han children. 29761786 2018
CUI: C0004096
Disease: Asthma
Asthma
0.500 GeneticVariation disease BEFREE JAK-3 mediates cytokine signaling, while DNA methylation in the ADRB2 gene decreases asthma symptom severity. 29956621 2018
CUI: C0004096
Disease: Asthma
Asthma
0.500 Biomarker disease BEFREE The combination of inhaled long-acting β2-adrenoreceptor (LABA) and inhaled glucocorticoid (ICS) is a major therapy for asthma. 28987803 2018
CUI: C0004096
Disease: Asthma
Asthma
0.500 GeneticVariation disease BEFREE The findings suggest that the Arg16Gly and Gln27Glu polymorphisms in the β2-AR gene are associated with asthma severity and response to therapy and might be used in personalized treatment for these patients in the future. 30178312 2018
CUI: C0004096
Disease: Asthma
Asthma
0.500 GeneticVariation disease BEFREE Leveraging electronic health records to assess the role of ADRB2 single nucleotide polymorphisms in predicting exacerbation frequency in asthma patients. 30334910 2018
CUI: C0004096
Disease: Asthma
Asthma
0.500 AlteredExpression disease BEFREE Effects of Aspergillus fumigatus on glucocorticoid receptor and β2-adrenergic receptor expression in a rat model of asthma. 28696809 2018
CUI: C0004096
Disease: Asthma
Asthma
0.500 GeneticVariation disease BEFREE To assess the clinical value of ADRB2 rs1042713 in children with asthma using LABA, a randomized clinical trial with well-defined outcomes is needed. 29992699 2018
CUI: C0004096
Disease: Asthma
Asthma
0.500 Biomarker disease BEFREE Bronchial asthma (BA) is a chronic inflammatory disorder of airways for which the effective therapies include inhaled corticosteroids (ICS) and short-acting β2-adrenoreceptor agonist (SABA). 28781336 2017
CUI: C0004096
Disease: Asthma
Asthma
0.500 Biomarker disease BEFREE Over 11 years of follow-up in 4 million Norwegians, the β2AR agonist salbutamol, a brain-penetrant asthma medication, was associated with reduced risk of developing PD (rate ratio, 0.66; 95% confidence interval, 0.58 to 0.76). 28860381 2017
CUI: C0004096
Disease: Asthma
Asthma
0.500 Biomarker disease BEFREE Several mechanisms have been proposed regarding the risk of regular use of β2-agonists, such as masking patients' perception of worsening asthma, desensitization and downregulation of the β2-adrenoreceptor, pro-inflammatory effects of β2-agonists, pharmacogenetic effects of β2-adrenoreceptor polymorphisms and age related differences in pathophysiology of asthma. 27515731 2017
CUI: C0004096
Disease: Asthma
Asthma
0.500 Biomarker disease BEFREE In addition, early intervention with cholinergic receptor muscarinic (ChRM)-3 blocker reversed the progression of AHR in the neonatal exposure model, whereas β2-adrenoceptor agonists had no such effect. 28619712 2017
CUI: C0004096
Disease: Asthma
Asthma
0.500 Biomarker disease BEFREE Targeting the pathways leading to β2-adrenoceptor dysfunction will likely provide novel therapies to improve the efficacy of β2-agonists in asthma. 28950943 2017
CUI: C0004096
Disease: Asthma
Asthma
0.500 GeneticVariation disease BEFREE The Arg/Arg homozygosity at codon 16 of the beta-2-adrenoreceptor (ADRB2) gene has been thought to predispose asthma patients to a poorer therapeutic response to beta-2-mimetics, or to worse control of the disease. 28093224 2017
CUI: C0004096
Disease: Asthma
Asthma
0.500 GeneticVariation disease BEFREE ADRB2 Polymorphism and Salbutamol Responsiveness in Northern Indian Children with Mild to Moderate Exacerbation of Asthma. 27029682 2016
CUI: C0004096
Disease: Asthma
Asthma
0.500 GeneticVariation disease BEFREE In south Indian population, the ADRB2 Thr164Ile polymorphism may not form susceptible variant to develop asthma, however, it can form a predictive maker for bronchodilator (Salbutamol) response in severe asthmatics. 27450915 2016